Brian Orelli, PhD

Amarin falls 60% because of an unvalidated surrogate endpoint. Companies such as Sarepta Therapeutics, using surrogate endpoints, should take note.

For Amarin's Vascepa to beat GlaxoSmithKline's Lovaza, the Food and Drug Administration advisory committee needs to convince the agency that the drug will improve outcomes, unlike Merck's Cordaptive. But the advisers' comments will be more important than the actual vote, as Orexigen investors have learned.

Tweets about Aegerion Pharmaceuticals, ARIAD Pharmaceuticals, and Gilead Sciences highlight the risks and benefits of investing in biotech.

VIVUS and Auxilium Pharmaceuticals team up to compete against Eli Lilly's Cialis and Pfizer's Viagra.

ClinicalTrials.gov, advisory committee meetings, and updates on the flu are all affected.

Gilead's fortune could create competition for Roche, Johnson & Johnson, and Pharmacyclics.

ARIAD Pharmaceuticals gets cut down on safety data, which seems to be good news for Novartis and Bristol-Myers Squibb, which have competing drugs.

Sarepta, BioMarin, and Sanofi are doing a good job; Prosensa, GlaxoSmithKline and PTC Therapeutics should take note.

Learning about biotech investing from the tweetosphere.

Cosmetic treatments could pick up as the economy improves

Management isn't always the best to listen to.

Achillion Pharmaceuticals is in big trouble.

The biotech bubble is here, and its end is coming -- eventually. Here are some ideas on how to handle it.

Having capital to fund the biotech pipeline helps. A lot.

Studying the potential upside of Orexigen by comparing it to similar products.

Sorting through the noise to bring insight and investment lessons.

AbbVie and Galapagos's cystic fibrosis drug deal shouldn't threaten Vertex.

Unfortunately, it's still in just 10 patients.

When looking at buzz in the media about biotech companies, read and verify.

VIVUS makes a third attempt to get its obesity drug Qsymia approved in the EU.